Podcast Summary: Building Trust and Modernizing Healthcare with FDA Commissioner Dr. Marty Makary
Becker’s Healthcare Podcast | September 25, 2025
Host: Scott Becker
Guest: Dr. Marty Makary, FDA Commissioner
Episode Overview
This episode features a candid conversation between Scott Becker and Dr. Marty Makary, current FDA Commissioner and renowned physician-leader. Focused on modernizing healthcare, restoring public trust, and confronting the challenges of regulatory absolutism, the discussion covers the FDA’s evolving role, vaccine controversies, drug approval timelines, food safety reforms, and the importance of transparent, humble leadership in a polarized era.
Key Discussion Points and Insights
Dr. Makary’s Background and Career Philosophy
- Dr. Makary reflects on his diverse, “nomadic” medical career and research across specialties, highlighting how challenging medical dogma with data prepared him for FDA leadership.
- “Challenging that dogma with good data and evidence is an incredible exercise that we need more of.” (Dr. Makary, 02:48)
- He emphasizes viewing medicine holistically, advocating for inquiry into root causes of disease rather than just treating symptoms (e.g., chronic childhood diseases linked to food/environment).
The Politics of Healthcare and Vaccine Schedule Explosion
- Becker and Makary discuss how healthcare, especially around vaccines, has become highly politicized and tribal.
- Increase in childhood vaccines: from 5-7 vaccines decades ago to “65 or 68 to 78” today (03:21).
- Makary highlights the erosion of public trust, warning against “tribalism in medicine” and advocating for radical transparency and humility.
- “Trust in doctors and hospitals … went from 71% of the public … in 2019 down to 40% … last year. … The way you rebuild public trust is to show humility.” (Dr. Makary, 06:31)
Regaining Trust Through Transparency and Nuanced Communication
- Makary outlines FDA’s moves toward transparency:
- Publishing drug rejection letters
- Publishing evidence-based vaccine regulation articles (06:55)
- He criticizes the suppression and censoring of divergent opinions, arguing it breeds distrust.
Managing Vaccine Schedules and Parental Concerns
- Dr. Makary stresses the need for dialogue, not dogma, when engaging with families about vaccines. He opposes “all or nothing” approaches by pediatricians and supports considering alternate (international) vaccine schedules.
- “If somebody comes in and says, I want to use the Japanese vaccine schedule … I think that should be a conversation and we should have less tribalism.” (Dr. Makary, 10:32)
- Notes that countries like Japan and Germany mandate 8-10 vaccines (e.g., MMR and polio) while the U.S. can be more rigid.
Fighting Absolutism in Regulation
- Regulatory absolutism limits innovation (e.g., requiring outdated animal studies, stagnation in baby formula and sunscreen products).
- Makary advocates updating processes to match scientific advances, especially in AI and medical devices.
- Example: No new sunscreen formulas in the U.S. due to rigid regulations, unlike Europe (13:37).
Modernizing FDA Drug Approval
- Two priorities: cut red tape, and reduce idle time during clinical trials.
- Proposes “Priority Review Program” for drugs that:
- Secure domestic manufacturing
- Meet large public health needs
- Reduce downstream healthcare utilization
- Offer fair pricing
- Utilizing AI tools for faster review and aiming for drug decisions “in weeks instead of a year.” (17:13)
Tylenol, Autism, and Scientific Discourse
- Explains recent FDA moves around prenatal Tylenol use and autism risk:
- Cites emerging associations from reputable studies
- Emphasizes the goal is transparent warning labels, not bans
- Announces likely approval of new autism treatments (e.g., leucovorin) based on real-time evidence.
- “When the dean of the Harvard School of Public Health has a safety concern and it is supported by 27 studies, we felt obligated to let the public know.” (Dr. Makary, 19:54)
Food Policy and Child Health
- Reasserts that “F” in FDA stands for food. Current initiatives:
- Phasing out petroleum-based food dyes, titanium dioxide, and preservatives like BHT from U.S. foods
- Applauding industry leaders (e.g., Mars, Tyson, Sam’s Club) and hospitals (Tampa General) implementing healthier food policies
- New SNAP waivers let states restrict taxpayer funds for buying sugary drinks/junk food
- “We want to see more health promoted. And if a hospital is making a dramatic switch to healthier food … we're going to give them kudos and credit and all the attention they deserve.” (Dr. Makary, 23:51)
Navigating Public Messaging on Vaccines
- Warns against being framed as “anti-vax” due to nuanced, evidence-based positions.
- Aims for centrist messaging: Strong support for essential vaccines while remaining flexible on less critical ones (25:00).
- “The questions that RFK is asking about vaccines, if we’re being honest, are questions that many Americans are asking.” (Dr. Makary, 25:28)
- Emphasizes that final regulatory decisions are evidence-driven and non-partisan.
Future FDA Priorities and Innovations
- Two agency goals: more cures delivered promptly, and healthier food supply
- Upcoming pipeline highlights:
- Promising new treatments for type 1 diabetes, pediatric blindness, neurodegenerative diseases, and certain cancers
- New “big data” project to track post-approval drug safety in near-real-time, avoiding historical tragedies (like Vioxx, OxyContin).
- Push for a universal, long-lasting flu vaccine.
- Major focus: Fast-tracking treatments for PTSD, esp. for veterans.
- “We lose 8,000 veterans to suicide a year … We owe it to them to get the decision out promptly on any potentially promising treatment for PTSD.” (Dr. Makary, 28:55)
Notable Quotes and Memorable Moments
-
On transparency and humility:
“We’re doing everything we can at the FDA to try to be radically transparent … because I think the way you rebuild public trust is to show humility.”
(Dr. Makary, 06:31) -
On pharmaceutical advertising enforcement:
“Last year, the FDA sent out zero. And the year before they sent out one enforcement letter, I sent out 100. And I sent out 1,500 letters warning the industry that we're going to take this piece very seriously.”
(Dr. Makary, 09:51) -
On vaccine schedules:
“If somebody comes in and says, I want to use the Japanese vaccine schedule for my child … I think that should be a conversation and we should have less tribalism.”
(Dr. Makary, 10:32) -
On absolutism and modernization:
“We've got to modernize. We've got to update the regulatory process with the way that science is advancing.”
(Dr. Makary, 14:16) -
On new autism research:
“When the dean of the Harvard School of Public Health has a safety concern and it is supported by 27 studies, we felt obligated to let the public know and to include that information on the label of acetaminophen.”
(Dr. Makary, 19:54) -
On food safety reform:
“We have a huge jurisdiction over food … and I’m proud to report that the majority of U.S. manufacturers have agreed to our plan to remove all nine petroleum-based food dyes from the U.S. food supply.”
(Dr. Makary, 22:22)
Important Segment Timestamps
- Career reflections & philosophy: 00:46 – 03:50
- Politicization & trust in medicine: 03:50 – 07:19
- Vaccine controversy & parental engagement: 08:41 – 11:43
- Absolutism in regulation & need for modernization: 13:24 – 15:41
- Accelerating FDA modernization & AI: 15:41 – 18:00
- Tylenol, autism, and scientific labeling: 18:39 – 21:23
- Food and chemical safety initiatives: 22:08 – 24:18
- Public messaging and essential vaccines: 24:18 – 27:00
- Future FDA priorities & health innovations: 27:15 – 29:38
Conclusion
Dr. Makary’s conversation offers rare transparency and nuance from an FDA leader. He argues for data-driven modernization, humility, and discussion over doctrine while aiming to rapidly expand Americans’ access to safer food and breakthrough therapies. Through pragmatic reforms and open communication, he hopes to restore credibility and deliver meaningful health advances for all.